





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07C 69/74, 61/06, 61/20, 49/105, 49/297, 49/395, 49/597, C07D 261/20, 233/54, 341/00	A1	(11) International Publication Number: WO 99/33781 (43) International Publication Date: 8 July 1999 (08.07.99)
(21) International Application Number: PCT/US98/26871 (22) International Filing Date: 17 December 1998 (17.12.98) (30) Priority Data: 60/069,956 60/085,252 17 December 1997 (17.12.97) 13 May 1998 (13.05.98) US US (71) Applicant (for all designated States except US): BIOCRIST PHARMACEUTICALS, INC. [US/US]; 2190 Parkway Lake Drive, Birmingham, AL 35244 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BABU, Yarlagadda, S. [IN/US]; 3441 Strollway Drive, Birmingham, AL 35226 (US). CHAND, Pooran [IN/US]; 509 Creekwood Place, Birmingham, AL 35226 (US). MONTGOMERY, John, A. [US/US]; 2215 Brookshire Place, Birmingham, AL 35213 (US). (74) Agents: AMERNICK, Burton, A. et al.; Pollock, Vande Sande & Amernick, Suite 800, 1990 M Street, N.W., Washington, DC 20036 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. 2000 03071-8 IP05's copy


(54) Title: SUBSTITUTED CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS



(I)



(II)



(III)

(57) Abstract

Compounds represented by formulae (I, II or III), wherein U is CH, O, or S; Z is $-C(R_2)(R_3)$, $-CH-N(R_2)(R_3)$, $C(R_3)[(CH_2)_nR_2]$, $CH-C(R_3)(R_8)(CH_2)_nR_2$, $C[(CH_2)_nR_2]-[CH(R_3)(R_8)]$, $C(R_3)[CH[(CH_2)_nR_2](R_8)]$; R_1 is H, $(CH_2)_nOH$, $(CH_2)_nNH_2$, $(CH_2)_nNR_{10}R_{11}$, $(CH_2)_nOR_{11}$, $(CH_2)_nSR_{11}$, or $(CH_2)_n$ halogen; R_9 is $(CH_2)_nCO_2H$, $(CH_2)_nSO_3H$, $(CH_2)_nPO_3H_2$, $(CH_2)_nNO_2$, $CH(SCH_3)_3$, esters thereof, or salts thereof.